================================================================================
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
----------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
August 2, 2006
---------------------------------
Date of Report
(Date of earliest event reported)
ADVANCIS PHARMACEUTICAL CORPORATION
--------------------------------------------------
(Exact Name of Registrant as Specified in Charter)
Delaware 000-50414 52-2208264
---------------------------- ------------ -------------------
(State or Other Jurisdiction (Commission (IRS Employer
of Incorporation) File Number) Identification No.)
20425 Seneca Meadows Parkway, Germantown, Maryland 20876
-------------------------------------------------- ----------
(Address of Principal Executive Offices) (ZIP Code)
Registrant's telephone number, including area code: (301) 944-6600
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
================================================================================
ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION.
On August 2, 2006, Advancis Pharmaceutical Corporation issued a
press release announcing its financial results for the three months and six
months ended June 30, 2006. A copy of the release is furnished as Exhibit 99.1
to this Current Report on Form 8-K.
The information in this Form 8-K and the Exhibit attached hereto
shall not be deemed "filed" for the purposes of Section 18 of the Securities
Exchange Act of 1934, nor shall it be deemed incorporated by reference in any
filing under the Securities Act of 1933, except as shall be expressly set forth
by specific reference in such filing.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.
(d) Exhibits
Exhibit Description
------- -----------------------------------------------------
99.1 Press Release issued August 2, 2006
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ADVANCIS PHARMACEUTICAL CORPORATION
Date: August 2, 2006 By: /s/ Robert C. Low
------------------------------
Robert C. Low
Vice President, Finance and
Acting Chief Financial Officer